PTPI (petrospharma.com) יחס שווי שוק לשווי בספרים
The history of the market cap to book value ratio on the GURU.Markets chart shows that Petros Pharmaceuticals (PTPI) -0.01 is hitting a new level. This price action reflects the defensive nature of the sector, which remains independent of global crises. Growth is supported by plans to launch Stendra into OTC and the development of telemedicine, although poor management transparency and limited commercialization experience create certain risks for shareholders.
%3A%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%91%D7%99%D7%97%D7%A1%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvrk6wqv.ssk-7as46ww&start=20220704&end=20261028&filename=GURU_Markets_-_PTPI_-_Petros-Pharmaceuticals_-_Market-Capitalization-to-Net-Assets "PTPI יחס שווי שוק לערך בספרים Petros Pharma (04.07.2022 - 28.06.2025) | 👁️GURU.Markets👁️")
פילוחי מדדים פיננסיים ומדדי שוק עבור Petros Pharmaceuticals Inc (PTPI)
When assessing the resilience of Petros Pharmaceuticals (PTPI) to market shocks, it is essential to analyze its net asset value. Business revenues are generated by the sale of urological drugs for men's health. This chart of the market capitalization to book value ratio reflects the premium investors pay for every dollar of equity. A high coefficient signals optimism but reduces the margin of safety, which determines the risk of a correction should the trend reverse.